Flu cases in Scotland drop by more than a third

Scotland's lab-confirmed flu cases fell to 1,297 in the week to 21 December from 1,994 the prior week, while provisional flu-related hospital admissions declined to 679 from 950, indicating an encouraging near-term easing in healthcare pressure. Weekly flu deaths rose modestly to 73 in the week to 15 December (from 67), but national statistics suggest the rate of increase is slowing; Public Health Scotland cautions the season is not over, notes influenza A is currently dominant and warns flu B could drive a second wave in early 2026, urging vaccination and mitigation measures.

Analysis

Market structure: A ~35% week-on-week drop in lab-confirmed cases (1,994 → 1,297) and ~29% fall in hospitalisations (950 → 679) materially reduces short-term stress on diagnostics, emergency services and sick‑leave‑sensitive sectors. Winners: vaccine manufacturers (seasonal uptake + late‑season demand for flu B), OTC cold/flu consumer names, and travel/leisure if social activity normalises; losers: short‑term revenue for urgent care/diagnostics labs and firms that priced in prolonged absenteeism. Pricing power shifts toward vaccine producers in Q1 if flu B emerges because demand is time-concentrated and procurement windows are tight.

Risk assessment: Tail risks include a second flu B wave in Jan–Mar that could reverse declines (historical precedent: mid‑season rebounds; deaths doubled week‑on‑week previously), vaccine supply shortages, or regulatory scrutiny of vaccine efficacy. Time horizons: immediate (days) — modest boost to consumer activity over Christmas; short (weeks/months) — travel/leisure re‑rating or reversal; long (quarters) — concentrated vaccine revenue in Q1 and potential capex/supply chain effects. Hidden dependencies: NHS procurement timing, winter staff levels, and cross‑immunity with other respiratory viruses could amplify moves.

Trade implications: Direct plays are long vaccine makers and selective travel/leisure exposure with defined-risk options rather than outright leverage; consider short positions in retail staples that benefited from stay‑at‑home behaviour if cases keep falling. Use pair trades to express relative views (vaccine manufacturer vs defensive supermarket) and buy tail protection (puts) sized to 0.5–1% of portfolio to guard against a Jan‑Feb rebound. Entry should be phased: initial positions now, scale on confirmation of two consecutive weekly declines or on PHS thresholds.

Contrarian angles: Consensus may underweight probability of a Jan–Mar flu B rebound — the market could be underpricing options skew on UK leisure names. Overdone risk: immediate travel optimism could be reversed by a 20%+ reacceleration in hospitalisations within 2 weeks. Actionable monitor triggers: if weekly cases rise >25% W/W for two consecutive weeks or hospitalisations rise >20% W/W, flip travel longs to hedged positions within 7 days.

Key Decisions for Investors

• Establish a 2–3% long position in GSK.L (GlaxoSmithKline) to capture Q1 2026 influenza vaccine upside; set a 12% stop‑loss and target +15–25% by end of Q1 2026, scale in on two consecutive weekly declines in PHS data.
• Buy a defined‑risk call spread on EZJ.L (easyJet) or IAG.L (IAG) expiring March 2026: buy 15% OTM call / sell 35% OTM call, total notional 1–2% portfolio to express a short‑term travel recovery while capping downside.
• Pair trade: long CSL.AX (Seqirus exposure) 1% vs short TSCO.L (Tesco) 1% over 3 months — vaccine maker to outperform defensive supermarket if influenza declines and discretionary spend rebounds; unwind if hospitalisations rise >20% W/W.
• Buy tail protection: purchase Feb–Mar 2026 puts on a UK leisure ETF or IAG.L at ~15% OTM sized to 0.5–1% of portfolio value to hedge a Jan–Feb flu B rebound scenario.
• Operational trigger: monitor PHS weekly metrics — if lab‑confirmed cases increase >25% W/W for two consecutive weeks or hospital admissions >20% W/W, reduce travel/leisure exposure by 50% and increase vaccine/diagnostic longs within 7 days.